Table 3. Multivariable analyses for the factors associated with PFS and TTCST in patients with OMD NSCLC while on novel systemic therapies.
| Variable | PFS from SBRT | TTCST from SBRT | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| GTV | 1.01 | 0.10–1.03 | 0.103 | 1.02 | 0.10–1.03 | 0.088 | |
| Age | 1.02 | 0.98–1.06 | 0.365 | 1.01 | 0.96–1.06 | 0.746 | |
| Male vs. female | 2.10 | 0.99–4.35 | 0.052 | 2.34 | 0.99–5.53 | 0.053 | |
| Osimertinib vs. ICI | 2.20 | 1.01–4.82 | 0.048 | 2.83 | 1.09–7.33 | 0.032 | |
| OprogD vs. OpersisD | 2.73 | 1.17–6.39 | 0.020 | 3.07 | 1.12–8.45 | 0.030 | |
PFS, progression-free survival; TTCST, time to change of systemic treatment; OMD, oligometastatic disease; NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiation therapy; GTV, gross tumor volume; ICI, immune checkpoint inhibitor; OprogD, oligoprogressive disease; OpersisD, oligopersistent disease.